IL290071B1 - Solid forms of n-tert-butyl-4[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide - Google Patents

Solid forms of n-tert-butyl-4[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide

Info

Publication number
IL290071B1
IL290071B1 IL290071A IL29007122A IL290071B1 IL 290071 B1 IL290071 B1 IL 290071B1 IL 290071 A IL290071 A IL 290071A IL 29007122 A IL29007122 A IL 29007122A IL 290071 B1 IL290071 B1 IL 290071B1
Authority
IL
Israel
Prior art keywords
compound
polymorph
degrees
solvent
theta
Prior art date
Application number
IL290071A
Other languages
English (en)
Hebrew (he)
Other versions
IL290071A (en
Original Assignee
Tmem16A Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tmem16A Ltd filed Critical Tmem16A Ltd
Publication of IL290071A publication Critical patent/IL290071A/en
Publication of IL290071B1 publication Critical patent/IL290071B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL290071A 2019-07-25 2020-07-24 Solid forms of n-tert-butyl-4[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide IL290071B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1910664.0A GB201910664D0 (en) 2019-07-25 2019-07-25 Novel forms of compound
PCT/GB2020/051779 WO2021014167A1 (en) 2019-07-25 2020-07-24 Solid forms of n-tert-butyl-4[[2-(5-chloro-2-hydroxy-phneyl)acetyl]amino]pyridine-2-carboxamide

Publications (2)

Publication Number Publication Date
IL290071A IL290071A (en) 2022-03-01
IL290071B1 true IL290071B1 (en) 2026-02-01

Family

ID=67990591

Family Applications (1)

Application Number Title Priority Date Filing Date
IL290071A IL290071B1 (en) 2019-07-25 2020-07-24 Solid forms of n-tert-butyl-4[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide

Country Status (19)

Country Link
US (1) US12281077B2 (https=)
EP (1) EP4003960A1 (https=)
JP (1) JP7627683B2 (https=)
KR (1) KR20220087430A (https=)
CN (1) CN114585607B (https=)
AU (1) AU2020318943A1 (https=)
BR (1) BR112022001276A2 (https=)
CA (1) CA3145285A1 (https=)
CL (1) CL2022000187A1 (https=)
CO (1) CO2022002046A2 (https=)
CR (2) CR20220079A (https=)
GB (1) GB201910664D0 (https=)
IL (1) IL290071B1 (https=)
MX (1) MX2022000891A (https=)
MY (1) MY207877A (https=)
PE (1) PE20221407A1 (https=)
PH (1) PH12022550193A1 (https=)
UA (1) UA129300C2 (https=)
WO (1) WO2021014167A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176767A1 (en) * 2003-10-30 2005-08-11 Laval Chan Chun Kong Pyridine carboxamide and methods for inhibiting HIV integrase
CA2658362A1 (en) 2006-06-29 2008-01-03 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors
WO2016042114A1 (en) * 2014-09-19 2016-03-24 F. Hoffmann-La Roche Ag Cxcl14 as a biomarker of hedgehog pathway activity for the diagnosis, prognosis and treatment of idiopathic pulmonary fibrosis
US11358947B2 (en) 2017-04-17 2022-06-14 The Regents Of The University Of California Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel TMEM16A
GB201801355D0 (en) * 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
CA3145285A1 (en) 2021-01-28
GB201910664D0 (en) 2019-09-11
AU2020318943A1 (en) 2022-03-17
JP2022542918A (ja) 2022-10-07
BR112022001276A2 (pt) 2022-03-22
JP7627683B2 (ja) 2025-02-06
KR20220087430A (ko) 2022-06-24
PH12022550193A1 (en) 2023-01-09
MX2022000891A (es) 2022-05-26
EP4003960A1 (en) 2022-06-01
US20220220074A1 (en) 2022-07-14
US12281077B2 (en) 2025-04-22
CN114585607B (zh) 2025-11-14
CL2022000187A1 (es) 2022-10-07
CO2022002046A2 (es) 2022-06-10
CR20220079A (es) 2022-06-28
CR20250316A (es) 2025-08-27
UA129300C2 (uk) 2025-03-12
CN114585607A (zh) 2022-06-03
IL290071A (en) 2022-03-01
WO2021014167A1 (en) 2021-01-28
PE20221407A1 (es) 2022-09-20
MY207877A (en) 2025-03-25

Similar Documents

Publication Publication Date Title
EP3743406B9 (en) Tmem16a modulators
EA016580B1 (ru) Соль янтарной кислоты 1-[2-(2-хлор-4-{[(r)-2-гидрокси-2-(8-гидрокси-2-оксо-1,2-дигидрохинолин-5-ил)этиламино]метил}-5-метоксифенилкарбамоил)этил]пиперидин-4-илового эфира бифенил-2-илкарбаминовой кислоты и ее применение для лечения легочных расстройств
US12415793B2 (en) Modulators of TMEM16A for treating respiratory disease
US12281077B2 (en) Solid forms of n-tert-butyl-4[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide
WO2021014168A1 (en) Solid forms of 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-n-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide
RU2843949C2 (ru) Твердые формы n-трет-бутил-4[[2-(5-хлор-2-гидроксифенил)ацетил]амино]пиридин-2-карбоксамида
HK40068903A (en) Solid forms of n-tert-butyl-4[[2-(5-chloro-2-hydroxy-phneyl)acetyl]amino]pyridine-2-carboxamide
WO2021014169A1 (en) Crystalline form of 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-n-cyclohexyl-pyridine-2-carboxamide
EP4003977B1 (en) Pyridine derivatives as calcium-activated chloride channel modulators
HK40067765B (zh) 用於治疗呼吸系统疾病的tmem16a的调节剂
CN116745267A (zh) 用于治疗呼吸系统疾病的苯并咪唑衍生物
HK40100262A (zh) 用於治疗呼吸系统疾病的苯并咪唑衍生物
HK40067765A (en) Modulators of tmem16a for treating respiratory disease
HK40042091A (en) Tmem16a modulators
HK40042091B (en) Tmem16a modulators
CN103087137A (zh) 一种21位为硫代烃基的糖皮质激素